Pacific Biosciences of California preprint applies Vega workflow to Parkinson disease research

Pacific Biosciences of California preprint applies Vega workflow to Parkinson disease research
PacBio Vega reveals new study

Pacific Biosciences of California has announced that one of the first preprints utilizing its PacBio Vega platform is now available.

The study showcases the accurate detection of mitochondrial heteroplasmy down to 1 percent using a single full-length mtDNA amplicon, with the workflow being applied to Parkinson disease research. The availability of this research highlights ongoing innovation in high-precision genetic sequencing and its potential impact on neurological disorder studies.

Pacific Biosciences of California recently introduced its Ampli-Fi workflow to enable HiFi sequencing with lower DNA input requirements, according to a company announcement. The firm also engaged researchers and industry participants during packed sessions and booth events at ESHG2026, drawing significant crowds in the final days of the conference, company event reports show. These developments reflect the company's continued activity in genetic sequencing.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.